Browse by category

Vogenx has initiated the EMERGE (VGX-001-013) study - its Phase 2b clinical trial evaluating mizagliflozin for the treatment of post-bariatric hypoglycaemia (PBH). There are currently no therapeutics approved by the FDA for the treatment of PBH. EMERGE is a randomised, placebo-controlled, double-blind, parallel-group Phase 2b study designed to enrol approximately 36 adults who underwent bariatric surgery more than 12 months prior and who experience recurrent reactive hypoglyc

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

MBX Biosciences has announced positive results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Amylyx Pharmaceuticals has acquired avexitide from Eiger BioPharmaceuticals, an investigational, first-in-class glucagon-like peptide-1...